GliaCure, Inc

🗓 Founded 2011👥 3 employees💰 Last funded Jun 2014
Research🌐 gliacure.com
Website LinkedIn
GliaCure is a pioneer in the development of novel therapeutics aimed at treating neurological and neuropsychiatric disorders of the brain. The company’s approaches are based on glial targets, a cell type in the brain that has previously been overlooked in drug discovery. The company has developed a small molecule clinical candidate – GC021109 – for a glial target that has two primary actions downstream of target engagement: the stimulation of phagocytosis and anti-inflammatory actions in which levels of pro-inflammatory cytokines are reduced. GC021109 is currently being developed primarily as a disease modifying treatment of Alzheimer’s disease; however, its dual phagocytosis and anti-inflammatory actions have the potential to affect other disorders. In addition to its program using GC021109, GliaCure has a pipeline program for the development of therapeutics for astrocytic targets related to additional disorders, such as depression and sleep consolidation.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2011
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in GliaCure, Inc?
GliaCure, Inc has 1 investors on record on gritt.io, 1 mid-stage.
When did GliaCure, Inc last raise funding?
The most recent investment in GliaCure, Inc recorded on gritt.io was in June 2014.
When was GliaCure, Inc founded?
GliaCure, Inc was founded in 2011.
What industry is GliaCure, Inc in?
GliaCure, Inc operates in Research. Find similar Research investors on gritt.io.